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journal homepage: http://www.elsevier.com/locate/pjnnsI have read with interest a review by Kotlęga and colleagues
[1]. The authors summarized the current clinical and
experimental data on the links between the use of statins
and intracranial bleeds, precisely intracerebral and sub-
arachnoid hemorrhages. They drew a ﬁrm conclusion that
there is no compelling evidence that indeed statins may
increase bleeding risk in neurological patients at risk of
cardiovascular disease receiving this highly effective class of
drugs to reduce blood cholesterol levels. Evidence on the link
between the statin use and bleeding is inconsistent and a
very recent meta-analysis of randomized controlled studies
showed that higher daily doses of statins are associated with
an increased risk of intracerebral hemorrhages [2]. However,
these ﬁndings did not affect the current recommendations in
patients with acute ischemic stroke or transient ischemic
attack. It is widely accepted that stroke prevention involves
lifestyle modiﬁcation and speciﬁc treatment, including
among others the use of statins and other lipid-lowering
drugs [3]. High-dose statins are of key importance in stroke
prevention among patients with asymptomatic carotid
stenosis [4].
The review did not pay attention to potential mechanisms
through which statins may increase bleeding risk of various
locations, including intracerebral bleeds. It is worth mention-
ing that based on various experimental studies, statin therapy
may favorably alter several steps of the blood coagulation
cascade [4]. Through down-regulation of tissue factor expres-
sion on monocytes and vascular cells as well as enhanced
thrombomodulin expression on endothelial cells, statins
reduce thrombin generation and increase the activity of the
protein C anticoagulant pathway leading to lower amounts of
activated factor V generated following injury, which contrib-
utes to reduced FXa-mediated prothrombin activation [5].
Consequently the ﬁnal result of statin use is decreased
ﬁbrinogen cleavage and thrombin-mediated platelet activa-
tion [5] and there is no rationale to rule out these systemic
anticoagulant effects in all vascular beds. Importantly,
anticoagulant effects of statins can be observed as early as
after 1–3 days of their administration [6]. Moreover, statins
have proﬁbrinolytic effects including decreased plasminogenactivator inhibitor type 1 (PAI-1) expression and formation of
less compact ﬁbrin clots that are more susceptible to lysis [5].
Favorable modulation of a ﬁbrin structure and function,
including loose ﬁber network, in subjects receiving statins is
a novel antithrombotic effect of these drugs, which are to some
extent related to their thrombin lowering actions. Of note,
despite the fact that statins were reported to have anticoagu-
lant properties, we found that bleeding rates were not
signiﬁcantly different in statin-users versus non-users. On
the other hand, Schmidt et al. reported that statin use, along
with oral or parenteral anticoagulation, was associated with
approximately 25% reduction in the risk of recurrent venous
thromboembolism at 3-year follow-up, without increasing the
risk of bleeding [7]. Taken together, anticoagulant and
proﬁbrinolytic effects of statins are subtle and detectable
locally mostly in response to vascular injury; they do not
signiﬁcantly increase bleeding risk in everyday practice. As
suggested in the review [1], the overall effect of statins on
hemostasis, regardless of their dosage, supported by interre-
lated anti-inﬂammatory, antioxidative and immunomodula-
tory actions, appears beneﬁcial in terms of thromboembolic
events [5]. Given however growing experimental data and
ongoing clinical large trials on the use of statins in subarach-
noid hemorrhage, a delicate hemostatic balance nicely
modulated by statins should be carefully observed and
especially the administration of these agents at a moderate-
to-high doses in the early phase of such hemorrhages might
lead to clinically evident prohemorrhagic effects. This effect is
likely to limit the everyday use of statins in patients
hospitalized for intracerebral and subarachnoid hemorrhages.
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